Posts

Effect-of-prior-therapy-on-BRAF-V600E-mutant-metastatic-colorectal-cancer

Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

An exploratory post-hoc analysis of the BEACON CRC study investigated the overall survival (OS) of encorafenib + cetuximab (doublet) and FOLFIRI (control) according to prior therapies (bevacizumab, oxaliplatin, FOLFOXIRI and anticancer therapy [ACT]) in BRAF V600E-mutant metastatic colorectal cancer (mCRC).